Filing Details

Accession Number:
0001415889-25-005908
Form Type:
4
Zero Holdings:
No
Publication Time:
2025-02-27 18:42:49
Reporting Period:
2025-02-10
Filing Date:
2025-02-27
Accepted Time:
2025-02-27 18:42:49
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
907654 Oruka Therapeutics Inc. ORKA Pharmaceutical Preparations (2834) 363855489
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1615979 Y Bong Koh C/O Venrock
7 Bryant Park, 23Rd Floor
New York NY 10018
No No Yes No
1698082 P Nimish Shah C/O Venrock
7 Bryant Park, 23Rd Floor
New York NY 10018
No No Yes No
1738048 Venrock Healthcare Capital Partners Iii, L.p. C/O Venrock
7 Bryant Park, 23Rd Floor
New York NY 10018
No No No No
1738053 Vhcp Management Iii, Llc C/O Venrock
7 Bryant Park, 23Rd Floor
New York NY 10018
No No Yes No
1750761 Vhcp Co-Investment Holdings Iii, Llc C/O Venrock
7 Bryant Park, 23Rd Floor
New York NY 10018
No No Yes No
1808512 Venrock Healthcare Capital Partners Eg, L.p. C/O Venrock
7 Bryant Park, 23Rd Floor
New York NY 10018
No No Yes No
1808518 Vhcp Management Eg, Llc C/O Venrock
7 Bryant Park, 23Rd Floor
New York NY 10018
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2025-02-10 574 $10.90 4,026,120 No 4 P Indirect By Funds
Common Stock Acquisiton 2025-02-11 9,593 $10.95 4,035,713 No 4 P Indirect By Funds
Common Stock Acquisiton 2025-02-12 8,971 $11.86 4,044,684 No 4 P Indirect By Funds
Common Stock Acquisiton 2025-02-13 14,950 $11.63 4,059,634 No 4 P Indirect By Funds
Common Stock Acquisiton 2025-02-14 88,794 $11.44 4,148,428 No 4 P Indirect By Funds
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Funds
No 4 P Indirect By Funds
No 4 P Indirect By Funds
No 4 P Indirect By Funds
No 4 P Indirect By Funds
Footnotes
  1. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $10.88 to $11.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
  2. Consists of (i) 835,614 shares held by VHCP3; (ii) 83,701 shares held by VHCP Co-3; and (iii) 3,106,805 shares held by VHCP EG.
  3. VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein.
  4. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $10.86 to $11.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
  5. Consists of (i) 837,271 shares held by VHCP3; (ii) 83,867 shares held by VHCP Co-3; and (iii) 3,114,575 shares held by VHCP EG.
  6. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.25 to $12.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
  7. Consists of (i) 838,821 shares held by VHCP3; (ii) 84,022 shares held by VHCP Co-3; and (iii) 3,121,841 shares held by VHCP EG.
  8. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.31 to $11.74 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
  9. Consists of (i) 841,404 shares held by VHCP3; (ii) 84,280 shares held by VHCP Co-3; and (iii) 3,133,950 shares held by VHCP EG.
  10. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.17 to $11.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
  11. Consists of (i) 856,747 shares held by VHCP3; (ii) 85,816 shares held by VHCP Co-3; and (iii) 3,205,865 shares held by VHCP EG.